These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37869024)

  • 1. Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab-Associated Conjunctivitis in Patients with Atopic Dermatitis.
    Patra V; Woltsche N; Cerpes U; Bokanovic D; Repelnig M; Joshi A; Perchthaler I; Fischl M; Vocanson M; Bordag N; Durdevic M; Woltsche J; Quehenberger F; Legat F; Wedrich A; Horwath-Winter J; Wolf P
    Ophthalmol Sci; 2024; 4(1):100340. PubMed ID: 37869024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab-associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis.
    Achten R; Thijs J; van der Wal M; van Luijk C; de Graaf M; Bakker D; de Boer J; van Wijk F; de Bruin-Weller M
    Allergy; 2023 Aug; 78(8):2266-2276. PubMed ID: 36934403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy.
    Achten R; Thijs J; van der Wal M; van Luijk C; Bakker D; Knol E; van Luin M; El Amrani M; Delemarre E; Elfiky AMI; de Boer J; van Wijk F; de Graaf M; de Bruin-Weller M
    Clin Exp Allergy; 2024 Apr; 54(4):241-252. PubMed ID: 38332535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation.
    Thormann K; Lüthi AS; Deniau F; Heider A; Cazzaniga S; Radonjic-Hoesli S; Lehmann M; Schlapbach C; Herzog EL; Kreuzer M; Zinkernagel MS; Akdis CA; Zysset-Burri DC; Simon HU; Simon D
    Allergy; 2024 Apr; 79(4):937-948. PubMed ID: 38317432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.
    Foley P; Kerdraon YA; Hogden JP; Shumack S; Spelman L; Sebaratnam DF; Su CS; Katelaris CH
    Australas J Dermatol; 2022 Nov; 63(4):421-436. PubMed ID: 36125089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice.
    Paganini C; Spelta S; Tofani L; Talamonti M; Bianchi L; Coassin M; Di Zazzo A; Galluzzo M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999383
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment.
    Simpson EL; Schlievert PM; Yoshida T; Lussier S; Boguniewicz M; Hata T; Fuxench Z; De Benedetto A; Ong PY; Ko J; Calatroni A; Rudman Spergel AK; Plaut M; Quataert SA; Kilgore SH; Peterson L; Gill AL; David G; Mosmann T; Gill SR; Leung DYM; Beck LA
    J Allergy Clin Immunol; 2023 Nov; 152(5):1179-1195. PubMed ID: 37315812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis.
    Maudinet A; Law-Koune S; Duretz C; Lasek A; Modiano P; Tran THC
    Ophthalmol Ther; 2019 Sep; 8(3):485-490. PubMed ID: 31230264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterising the chronicity of dupilumab-associated ocular surface disease: an analysis of a retrospective case series.
    Hébert M; Qi SR; You E; Mercier M; Laughrea PA
    BMJ Open Ophthalmol; 2022 May; 7(1):. PubMed ID: 36161848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate-to-severe atopic dermatitis.
    Hartmann J; Moitinho-Silva L; Sander N; Harder I; Häsler R; Rodriguez E; Haufe E; Kleinheinz A; Abraham S; Heratizadeh A; Weisshaar E; Schäkel K; Handrick C; Augustin M; Wollenberg A; Staubach-Renz P; Ertner K; Sticherling M; Schwarz B; Quist S; Wiemers F; Schenck F; Wildberger J; Tittmann L; Lieb W; Schmitt J; Werfel T; Weidinger S;
    Allergy; 2023 Aug; 78(8):2290-2300. PubMed ID: 37032440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis.
    Chiricozzi A; Di Nardo L; Gori N; Antonelli F; Pinto L; Cuffaro G; Piro G; Savino G; Tortora G; Peris K
    Exp Dermatol; 2023 Sep; 32(9):1531-1537. PubMed ID: 37357541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.
    Callewaert C; Nakatsuji T; Knight R; Kosciolek T; Vrbanac A; Kotol P; Ardeleanu M; Hultsch T; Guttman-Yassky E; Bissonnette R; Silverberg JI; Krueger J; Menter A; Graham NMH; Pirozzi G; Hamilton JD; Gallo RL
    J Invest Dermatol; 2020 Jan; 140(1):191-202.e7. PubMed ID: 31252032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.
    Gu C; Wu Y; Luo Y; Wang S; Yin H; Gao Y; Wang C; Yao X; Li W
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1064-1073. PubMed ID: 35344634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up.
    Bohner A; Topham C; Strunck J; Haynes D; Brazil M; Clements J; Simpson E; Chamberlain W
    Cornea; 2021 May; 40(5):584-589. PubMed ID: 32826648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.